AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03608137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cannabis and thought disorder in schizophrenia:clinical and neuroimaging relationships
Description: To investigate whether the level of cannabis use in schizophrenic patients influences the symptoms of psychic disorganization via modulation of cerebral connectivity between the temporal lobe and the putamen.
Study NCT03608137 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cannabis and thought disorder in schizophrenia:clinical and neuroimaging relationships
Description: To investigate whether the level of cannabis use in schizophrenic patients influences the symptoms of psychic disorganization via modulation of cerebral connectivity between the temporal lobe and the putamen.
Study NCT03094364 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gaming CI Therapy
Description: Intensive remote (via video game) therapy for upper extremity hemiparesis.
Study NCT03634566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetylecysteine
Description: N-Acetylecysteine 150 mg/kg diluted in 100 ml glucose 5 % over 40 minutes followed by NAC 12.5 mg/kg in 500 ml glucose 5% over 4 hours, followed by NAC 6.25 mg/kg for 2 postoperative days
Study NCT03634566 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ringer acetate continuous infusion at the same rate for 2 days.
Study NCT01344538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginger Root Extract (Pure Encapsulations)
Description: 2.0 g per day (10:1 extract)
Study NCT01344538 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: 2.0 g per day
Study NCT01267331 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow mononuclear cells injection
Description: Participants will receive direct intramyocardial injection of autologous bone marrow mononuclear cells during CABG.
Study NCT01267331 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: placebo intramyocardial injection
Description: Participants will receive between 10 and 15 placebo injections that consist of saline and 5% human serum albumin during CABG.
Study NCT03144193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical anti-aging cosmetic cream
Description: Topical anti-aging cosmetic cream
Study NCT03144193 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Topical anti-aging cosmetic cream
Description: Topical anti-aging cosmetic cream
Study NCT06082596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEBT-908 for injection
Description: Dose escalation phase：10 or 15、22.5、33.75、45mg/m2, intravenous drip, firstly single dose, after the observation period, the drug was administered continuously for 1 cycle (21 days), 3 times a week, continuous administration for 2 weeks and withdrawal for 1 week.~Dose expansion phase：15 or 22.5mg/m2，intravenous drip, 3 times a week, continuous administration for 2 weeks and withdrawal for 1 week，21 days as cycle.
Study NCT02442765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786
Study NCT02442765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03566615 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAP-straight
Description: This study is to detect any differences in the detection rate of adenomas using straight caps that will be attached to the colonoscope and to compare it to the control method where no cap is used in the colonoscopy procedure.
Study NCT03566615 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAP-daisy
Description: This study is to detect any differences in the detection rate of adenomas using daisy caps that will be attached to the colonoscope and to compare it to the control method where no cap is used in the colonoscopy procedure.
Study NCT03566615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water
Description: using water instead of traditional air insufflation to help insertion
Study NCT03226756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection
Description: Nivolumab 3 mg/kg, every 2 weeks
Study NCT02850263 — intervention group
Intervention type: DRUG
Intervention: Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
Description: Anti-VEGF exposure is defined as treatment with intravitreal aflibercept for the treatment of DMO by the patient.according to the prescribing physician.
Study NCT02850263 — intervention group
Intervention type: DRUG
Intervention: Anti-VEGF therapies including: Eylea Aflibercept, VEGF Trap-Eye, BAY86-5321) and Ophthalmologicals / Antineovascularisation agents (S01LA05)
Description: Anti-VEGF exposure is defined as treatment with intravitreal aflibercept or another agent \[Ophthalmologicals / Antineovascularisation agents (S01LA05)\] for the treatment of DMO by the patient.according to the prescribing physician.
Study NCT01866501 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EZ-IO
Study NCT04018300 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Description: 65 mg Fe as ferrous sulfate
Study NCT03163693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: receive dexmedetomidine 0.5 μg/kg
Study NCT03163693 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: receive equal volume of normal saline
Study NCT01395121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nilotinib
Description: nilotinib 400 mgs orally twice daily until disease progression or withdrawal from treatment
Study NCT00665756 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: second Trabeculectomy
Description: second trabeculectomy with mitomycin-c
Study NCT00665756 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ahmed Implant
Description: Ahmed silicone drainage device
Study NCT04734223 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neuroimaging Findings in Patients With COVID-19
Description: MR and BT Imaging
Study NCT03649711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90mg
Description: Ticagrelor Pill
Study NCT03649711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 90mg
Description: Ticagrelor Pill
Study NCT03649711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 75mg
Description: Clopidogrel Pill and a matching placebo to conceal frequency
Study NCT03649711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 81 mg
Description: Aspirin Pill
Study NCT03649711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg
Description: Aspirin Pill
Study NCT00301535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBOC-201 (hemoglobin glutamer-250 bovine)
Description: HBOC-201 is an investigational solution of purified, glutaraldehyde-polymerized bovine hemoglobin with a concentration of hemoglobin of 13 ± 1 g/dL
Study NCT04617886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sadness induction
Description: Sadness state will be induced with a Virtual Reality program. Mood induction will be done with an emotional induction procedure in virtual reality (Mood induction parks (Baños et al., 2006)). This technique has proven to be effective in previous studies (e.g., van Strien et al. 2013). Virtual reality software simulates an urban park and includes several methods of sadness induction: Velten's tasks (1968) (sentence formulations with negative content about the self; for example, I am not valuable, I see no future); visualization of a image bank with emotional content from the international system of emotional images (IAPS, Lang et al.,1999); listening to a piece of music and viewing a film scene that demonstrated his effectiveness in inducing positive affect (Donen et al. 1952; Eich and Metcalfe 1989; Gross and Levenson 1995), and an autobiographical memory test.
Study NCT04617886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Happiness induction
Description: Happiness state will be induced with a Virtual Reality program. Mood induction will be done with an emotional induction procedure in virtual reality (Mood induction parks (Baños et al., 2006)). This technique has proven to be effective in previous studies (e.g., van Strien et al. 2013). Virtual reality software simulates an urban park and includes several methods of sadness induction: Velten's tasks (1968) (sentence formulations with negative content about the self; for example, I am not valuable, I see no future); visualization of a image bank with emotional content from the international system of emotional images (IAPS, Lang et al.,1999); listening to a piece of music and viewing a film scene that demonstrated his effectiveness in inducing positive affect (Donen et al. 1952; Eich and Metcalfe 1989; Gross and Levenson 1995), and an autobiographical memory test.
Study NCT02174523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40mg lurasidone
Study NCT02174523 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01340937 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V419
Description: V419 (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate \[Meningococcal Outer Membrane Protein Complex\], and Hepatitis B \[Recombinant\] Vaccine) (from one of three lots) 0.5 mL intramuscular injection at 2, 4, and 6 months of age.
Study NCT04018300 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aspiron
Description: 65 mg Fe as iron-enriched koji culture, called AspironTM
Study NCT04018300 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Contains maltodextrin.
Study NCT02697695 — intervention group
Intervention type: OTHER
Intervention: Laboratory Examination
Description: Laboratory Examination before, 1 month, 3 month, 6 month and up to 12 month after LSK, LRNYGB, LOLGB
Study NCT01340937 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PENTACEL™
Description: PENTACEL™ 0.5 mL intramuscular injection at 15 months of age in the V419 groups and at 2, 4, 6, and 15 months of age in the control group
Study NCT01340937 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PENTACEL™
Description: PENTACEL™ 0.5 mL intramuscular injection at 15 months of age in the V419 groups and at 2, 4, 6, and 15 months of age in the control group
Study NCT01340937 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13™
Description: Prevnar 13™ 0.5 mL intramuscular injection at 2, 4, 6, and 15 months of age
Study NCT01340937 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar 13™
Description: Prevnar 13™ 0.5 mL intramuscular injection at 2, 4, 6, and 15 months of age
Study NCT01340937 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RotaTeq™
Description: RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
Study NCT01340937 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RotaTeq™
Description: RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
Study NCT01340937 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombivax HB vaccine
Description: Recombivax HB vaccine 0.5 mL intramuscular injection at 2 and 6 months of age
Study NCT02055534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional counseling
Description: Nutritional counseling consists in: personalized dietary prescription associated with regular (every 3 weeks) dietetic advise by a registered dietician. Follow-up evaluations take place also during the visits scheduled by the oncologists
Study NCT02055534 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: General dietary advices
Description: General dietary advices are provided. Follow-up evaluations take place during the visits scheduled by the oncologists
Study NCT01839240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Given IV or SC
Study NCT01839240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT01839240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Description: Given IV
Study NCT01839240 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04920591 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: doll treatment
Description: The doll used in the study is the empathy doll; these dolls are designed to obtain an optimal interaction with patients and to arouse empathy.
Study NCT00277888 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral route for hemodialysis
Study NCT00277888 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Jugular route for hemodialysis
Study NCT01808053 — intervention group
Intervention type: DEVICE
Intervention: BodyGuardian remote health monitoring system
Description: The remote health management system connects personal health sensors with secure mobile communication devices. It is also able to give immediate feedback to the user. The solution is a multi-tiered mobile health platform. The front-end includes an adhesive snap-strip body sensor (BodyGuardian) that can measure HR, ECG, respiration rate (RR), and activity which is FDA approved for detection of non-lethal cardiac arrhythmias. It can wirelessly communicate with off-body sensors such as a BP cuff and scale to incorporate BP and weight data based on automated algorithms and can solicit symptoms from the user. It can also be used as an event recorder inputting symptoms and recording simultaneous physiologic data.
Study NCT03867604 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Injection to the subcutaneous layer at upper trapezium level
Study NCT03867604 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fascia injection
Description: Injection to the fascia below upper trapezium muscle
Study NCT02442765 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03446183 — intervention group
Intervention type: BEHAVIORAL
Intervention: Smoking cessation workshops
Description: All the participants took part in smoking cessation workshops. The comparison of metabolic aspects was made between the smokers and non-smokers
Study NCT04283942 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent calorie restriction (ICR)
Description: Participants in ICR group were instructed to ensure 2 successive days of fasting-mimicking and 5 days of recovery per week. On fasting-mimicking days, the participants were instructed to consume approximately 500 kcal/day and they were provided with plant-based meal replacement to improve adherence and ensured adequate intake of micronutrients. In the rest 5 days of recovery per week, participants were allowed to consume their usual diet.~Participants will receive dietary counseling from experienced nutritionists and eat a balanced diet (macronutrient distribution of approximately 10-15% protein, 55-65% carbohydrate and 20-30% fat).They are required to write daily dietary log. Besides, they are required to maintain their exercise routines and record their daily steps using a unified pedometer (Redmi Smart Band, Xiaomi Corporation, China). The use of drugs affecting blood glucose and LFC will be avoided.
Study NCT04283942 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Continuous calorie restriction (CCR)
Description: Participants in CCR group were instructed to consume the prescribed calories (25 kcal / kg × \[height (cm) - 100\] kg) every day by eating conventional food without time restriction.~Participants will receive dietary counseling from experienced nutritionists and eat a balanced diet (macronutrient distribution of approximately 10-15% protein, 55-65% carbohydrate and 20-30% fat).They are required to write daily dietary log. Besides, they are required to maintain their exercise routines and record their daily steps using a unified pedometer (Redmi Smart Band, Xiaomi Corporation, China). The use of drugs affecting blood glucose and LFC will be avoided.
Study NCT00937404 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Poliorix
Description: All subjects receive three doses of Poliorix vaccine, administered intramuscularly into the upper right side of the thigh.
Study NCT01638052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25% Bupivacaine + Clonidine
Description: Patients will receive 2mL of 0.25% bupivacaine with 2mcg/ml of clonidine
Study NCT00230282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: 3 to 30 mg, IV
Study NCT00230282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: \[(2R,3R,4S,5R)-5-(6-amino-2-fluoro-purin-9-yl)- 3,4-dihydroxy-oxolan-2-yl\]methoxyphosphonic acid
Study NCT00230282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: (RS)-N,N-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
Study NCT00990327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apadenoson SPECT-MPI
Description: Apadenoson single bolus IV injection 100 or 150 ug
Study NCT00990327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apadenoson SPECT-MPI
Description: Apadenoson single bolus IV injection 100 or 150 ug
Study NCT00990327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine SPECT-MPI
Description: Single IV infusion for 6 minutes at a rate of 140 µg/kg body weight per minute.
Study NCT00990327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine SPECT-MPI
Description: Single IV infusion for 6 minutes at a rate of 140 µg/kg body weight per minute.
Study NCT02867618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib given intravenously twice a week for 3 consecutive weeks, on days 1, 2, 8, 9, 15, and 16 on the 28-day cycle. This will be in combination with the oral TGR-1202
Study NCT02867618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGR-1202
Description: Oral TGR-1202 will be given PO once daily on Days 1-28 . This will be given in combination with the intravenous Carfilzomib
Study NCT01893372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: 200 mg by mouth daily in a 28 day cycle.
Study NCT01893372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypomethylating Agent (HMA)
Description: The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study.
Study NCT02956759 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pan-retinal photocoagulation laser treatment
Description: PRP initially consists of 1200 - 1600 burns given over 2-3 sessions and separated by2-3weeks by 532-argon laser machine.
Study NCT02956759 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pan-retinal photocoagulation laser treatment
Description: PRP initially consists of 1200 - 1600 burns given over 2-3 sessions and separated by2-3weeks by 532-argon laser machine.
Study NCT02703870 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: verum tDCS
Description: real transcranial direct current stimulation,10 sessions, 2mA for 20 minutes
Study NCT01720992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A theory-based action planning toolkit
Description: The toolkit will be distributed to the participants for their use at home, like a 'homework assignment', for the purpose of enhancing their intention and practices of the suggested behaviours. The development of the booklet was guided by the theory of The Health Action Process Approach (HAPA), which suggests that one's intention can be foster by knowing that the new behaviour has positive outcomes as opposed to the negative outcomes that accompany the current behaviour; and planning (action planning and coping planning) serves as an operative mediator between intentions and behaviour (Schwarzer, 2008). Previous evidence has shown the applicability of the HAPA in changing people's health behaviours, e.g., physical exercise, breast self-examination, seat belt use, dietary behaviours, and dental flossing; and its generalizability has been confirmed by Schwarzer (2008).
Study NCT01720992 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: A theory-based action planning toolkit
Description: The toolkit will be distributed to the participants for their use at home, like a 'homework assignment', for the purpose of enhancing their intention and practices of the suggested behaviours. The development of the booklet was guided by the theory of The Health Action Process Approach (HAPA), which suggests that one's intention can be foster by knowing that the new behaviour has positive outcomes as opposed to the negative outcomes that accompany the current behaviour; and planning (action planning and coping planning) serves as an operative mediator between intentions and behaviour (Schwarzer, 2008). Previous evidence has shown the applicability of the HAPA in changing people's health behaviours, e.g., physical exercise, breast self-examination, seat belt use, dietary behaviours, and dental flossing; and its generalizability has been confirmed by Schwarzer (2008).